Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 4,807 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Phase 2 Interventional Results available

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

NCT02953457
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Olaparib, Tremelimumab
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 27, 2026, 1:24 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT07037901
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Interventions
IMG-007, Placebo
Drug
Lead sponsor
Inmagene LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
16
States / cities
Lancaster, California • Los Angeles, California • Ocala, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis

NCT04050865
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Dexamethasone, 0.4mg, Placebo plug with no drug
Drug · Device
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Colorado Springs, Colorado • Louisville, Kentucky • Raynham, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT02316353
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
C1-esterase inhibitor
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
6 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 27, 2026, 1:24 PM EDT
Active, not recruiting Phase 4 Interventional

A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)

NCT06101095
View directory record Official record
Conditions
Eosinophilic Oesophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

NCT03627767
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Fountain Valley, California • Fremont, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 27, 2026, 1:24 PM EDT
Completed No phase listed Observational

Mechanisms of Acute Asthma Exacerbations Through Molecular Analysis of Airway Secretions and Tissues

NCT00603629
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Not applicable Interventional Results available

Efficacy of the Quell Wearable Device for Chronic Overlapping Pain Conditions

NCT05540002
View directory record Official record
Conditions
Chronic Pain, Adults 21 and Older, Multiple Chronic Overlapping Pain Conditions, Hypersensitivity
Interventions
High Intensity Quell, Low Intensity Quell
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 99 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 4 Interventional Results available

Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis

NCT00828412
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
EpiCeram Skin Barrier Emulsion, Desonide Cream 0.05%
Device · Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
3 Months to 12 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

NCT00698451
View directory record Official record
Conditions
Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions
doxorubicin HCL liposome; bevacizumab; carboplatin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Horsham, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 2 Interventional

A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis

NCT04693195
View directory record Official record
Conditions
Chronic Pruritus, Atopic Dermatitis
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
28
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)

NCT03712228
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Factor XIIa antagonist monoclonal antibody, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
7
States / cities
Orange, California • Walnut Creek, California • Centennial, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 27, 2026, 1:24 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease

NCT00069329
View directory record Official record
Conditions
Nervous System Malformations, Arthropathy, Neurogenic, Urticaria, Papilledema
Interventions
anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 27, 2026, 1:24 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of Family Programs for Improving Child and Family Health and Development

NCT03367845
View directory record Official record
Conditions
Behavior, Infant
Interventions
Control, Sensitivity Intervention, Couples' Intervention, Sensitivity and Couples' Intervention
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
6 Months and older
Enrollment
1,005 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
2
States / cities
Fort Wayne, Indiana • South Bend, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma

NCT04305405
View directory record Official record
Conditions
Severe Uncontrolled Asthma
Interventions
Benralizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
6 Years to 14 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Orlando, Florida • Lincoln, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 27, 2026, 1:24 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Cyclosporine Vs Steroids in DRESS

NCT04988256
View directory record Official record
Conditions
DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
Interventions
Cyclosporine, Methylprednisolone and Prednisone
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Investigate the Tooth Whitening and Dentin Hypersensitivity Effectiveness of Two Experimental Toothpastes

NCT07297732
View directory record Official record
Conditions
Dentin Hypersensitivity
Interventions
Test Toothpaste 1, Test Toothpaste 2, Reference Toothpaste
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 65 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Insulin Sensitivity Study in Healthy Subjects

NCT02922426
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ALKS 3831, Olanzapine, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277743
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Placebo (for Dupilumab)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 27, 2026, 1:24 PM EDT
Completed No phase listed Observational

A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season

NCT00982163
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2009 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)

NCT00920621
View directory record Official record
Conditions
Asthma
Interventions
Vitamin D 3 cholecalciferol, Vitamin D3
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
876 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2023
U.S. locations
3
States / cities
San Diego, California • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sensitive Periods in Human Flavor Learning

NCT01667549
View directory record Official record
Conditions
Development
Interventions
Timing of Diet and Flavor Experience
Other
Lead sponsor
Monell Chemical Senses Center
Other
Eligibility
2 Weeks to 3 Weeks
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 27, 2026, 1:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating How Well Different Types of Light-sensitive Cells in the Eye Contribute to Its Focusing Ability

NCT07691463
View directory record Official record
Conditions
Monochromatic, L- and S-cone Modulation Only, L- and M-cone Modulation Only, M and S-cone Modulation Only
Interventions
Color
Other
Lead sponsor
Rochester Institute of Technology
Other
Eligibility
Up to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 27, 2026, 1:24 PM EDT
Completed No phase listed Observational

XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States

NCT05157087
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
16,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 27, 2026, 1:24 PM EDT